Galibra Neuroscience Secures FDA Designations for SSADH Gene Therapy
The U.S. Food and Drug Administration has granted both Orphan Drug and Rare Pediatric Disease designations to Galibra Neuroscience for its investigational gene therapy targeting SSADH deficiency. This regulatory milestone accelerates the development of what could become the first disease-modifying treatment for the ultra-rare neurometabolic disorder.
SSADH deficiency, a genetic condition caused by variants in the ALDH5A1 gene, disrupts GABA metabolism and leads to the buildup of toxic neuroactive metabolites. Patients currently face severe neurologic and psychiatric challenges, including epilepsy and intellectual disability, with medical options limited to symptomatic management. Galibra's gene replacement program, rooted in preclinical research from Boston Children's Hospital and Harvard Medical School, aims to correct the root cause of the disorder.
These FDA designations provide critical development incentives, including potential tax credits and fee waivers. Furthermore, the Rare Pediatric Disease designation offers the possibility of a Priority Review Voucher upon successful marketing approval. Dr. Alexander Rotenberg, founder of Galibra, stated that these milestones reinforce the company's commitment to addressing the underlying biology of the disease. The project continues to advance through IND-enabling activities with support from Aurelix Bio and the SSADH Association, as the team works toward initiating clinical trials.
Comments (0)
No comments yet. Be the first!